Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: drug pricing

ACR Commends CMS Decision to Withdraw Most Favored Nation Payment Model for Part B Drugs

  |  

ATLANTA—The American College of Rheumatology (ACR) today applauded the U.S. Centers for Medicare & Medicaid Services’ (CMS) decision to withdraw a proposed rule to implement the “Most Favored Nation” (MFN) payment model for Part B drugs. Leaders felt the policy would have dramatically disrupted patient access to critical therapies needed to manage rheumatic diseases and…

Trump Says He Will Allow States to Import Prescription Drugs to Lower Costs

Reuters Staff  |  

WASHINGTON (Reuters)—U.S. President Donald Trump said on Friday, Nov. 22, he will soon release a plan to let Florida and other states import prescription medicines to combat high drug prices. He blasted the Democrat-led U.S. House of Representatives for not going far enough in a drug-pricing bill. “We will soon be putting more options on…

Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases

Caroline Humer  |  

NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…

Trump Administration to Appeal Ruling Blocking Price Disclosure for Drug Ads

Carl O'Donnell  |  

(Reuters)—The Trump administration is appealing a court ruling that struck down its plan to compel pharmaceutical companies to disclose wholesale prices of their drugs in televisions advertisements. The U.S. Department of Health and Human Services (HHS) filed a notice of appeal on Wednesday, as it prepares to challenge the July federal court ruling. “If the…

White House Preparing Order that Would Cut Drug Prices for Medicare

Michael Erman and Carl O'Donnell  |  

(Reuters)—U.S. President Donald Trump is considering a sweeping executive order that would cut prices on virtually all branded prescription drugs sold to Medicare and other government programs, according to two industry sources who had discussions with the White House. The order under discussion would be much broader than the Administration’s previously disclosed proposal to lower…

White House Scraps Proposal to Lower U.S. Drug Prices

Caroline Humer  |  

(Reuters)—The Trump administration on Thursday scrapped one of its most ambitious proposals for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients. The decision represents a new setback to President Donald Trump’s efforts to…

Trump Slams Drugmakers, Vows to Let U.S. States Buy Cheaper Medicines Abroad

Reuters Staff  |  

WASHINGTON (Reuters)—U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs on Thursday and vowed to allow U.S. states to buy medicines from other countries if they cost less. Trump, who campaigned on a platform to reduce drug prices for U.S. consumers, has taken few concrete steps to lower medication costs…

U.S. to Require Drugmakers to Show Prices in TV Ads

Reuters Staff  |  

(Reuters)—U.S. Centers for Medicare & Medicaid Services on Wednesday said it will require drugmakers to disclose the list price for their prescription drugs in direct-to-consumer television advertisements, part of the Trump administration’s efforts to lower costs for U.S. consumers. The list price should be included if it is equal to or greater than $35 for…